Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 23
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Alwan, Sura Friedman, Jan M. and Chambers, Christina 2016. Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence. CNS Drugs, Vol. 30, Issue. 6, p. 499.


    Hanley, Gillian E. and Oberlander, Tim F. 2014. The effect of perinatal exposures on the infant: Antidepressants and depression. Best Practice & Research Clinical Obstetrics & Gynaecology, Vol. 28, Issue. 1, p. 37.


    Marroun, H. E. White, T. J. H. van der Knaap, N. J. F. Homberg, J. R. Fernandez, G. Schoemaker, N. K. Jaddoe, V. W. V. Hofman, A. Verhulst, F. C. Hudziak, J. J. Stricker, B. H. C. and Tiemeier, H. 2014. Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. The British Journal of Psychiatry, Vol. 205, Issue. 2, p. 95.


    ‘t Jong, Geert W. Einarson, Thomas Koren, Gideon and Einarson, Adrienne 2012. Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): A systematic review. Reproductive Toxicology, Vol. 34, Issue. 3, p. 293.


    Giardinelli, L. Innocenti, A. Benni, L. Stefanini, M. C. Lino, G. Lunardi, C. Svelto, V. Afshar, S. Bovani, R. Castellini, G. and Faravelli, C. 2012. Depression and anxiety in perinatal period: prevalence and risk factors in an Italian sample. Archives of Women's Mental Health, Vol. 15, Issue. 1, p. 21.


    Unger, Annemarie Metz, Verena and Fischer, Gabriele 2012. Opioid Dependent and Pregnant: What Are the Best Options for Mothers and Neonates?. Obstetrics and Gynecology International, Vol. 2012, p. 1.


    Xu, Fenglian Austin, Marie-Paule Reilly, Nicole Hilder, Lisa and Sullivan, Elizabeth A. 2012. Major depressive disorder in the perinatal period: using data linkage to inform perinatal mental health policy. Archives of Women's Mental Health, Vol. 15, Issue. 5, p. 333.


    Bellissima, Valentina Visser, Gerard HA Ververs, Tessa F Bel, Frank van Termote, Jacqueline UM van der Heide, Marja Florio, Pasquale Li Volti, Giovanni and Gazzolo, Diego 2011. Antenatal maternal antidepressants drugs affect Activin A concentrations in maternal blood, in amniotic fluid and in fetal cord blood. The Journal of Maternal-Fetal & Neonatal Medicine, Vol. 24, Issue. sup2, p. 31.


    Favrelière, S. Nourrisson, A. Jaafari, N. and Pérault Pochat, M.-C. 2010. Traitement par inhibiteurs sélectifs de la recapture de la sérotonine de la dépression chez la femme enceinte : risques pour le fœtus et le nouveau-né. L'Encéphale, Vol. 36, p. D133.


    Pearlstein, Teri and Star, Jami 2010. de Swiet's Medical Disorders in Obstetric Practice.


    Alwan, Sura and Friedman, Jan M. 2009. Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy. CNS Drugs, Vol. 23, Issue. 6, p. 493.


    Cowen, P.J. 2009.


    McClanahan, Kimberly K. 2009. Depression in Pregnant Adolescents: Considerations for Treatment. Journal of Pediatric and Adolescent Gynecology, Vol. 22, Issue. 1, p. 59.


    Rees, Anne-Marie Austin, Marie-Paule Owen, Catherine and Parker, Gordon 2009. Omega-3 deficiency associated with perinatal depression: Case control study. Psychiatry Research, Vol. 166, Issue. 2-3, p. 254.


    Belik, Jaques 2008. Fetal and Neonatal Effects of Maternal Drug Treatment for Depression. Seminars in Perinatology, Vol. 32, Issue. 5, p. 350.


    Fanaroff, A.A. 2008. Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates. Yearbook of Neonatal and Perinatal Medicine, Vol. 2008, p. 60.


    Frías, Jaime L. and Gilbert-Barness, Enid 2008. Human Teratogens: Current Controversies. Advances in Pediatrics, Vol. 55, Issue. 1, p. 171.


    Moulsdale, Wendy and Hermann, Susan 2008. In Utero Exposure to Selective Serotonin Reuptake Inhibitors: Evidence for Poor Neonatal Adaptation. Newborn and Infant Nursing Reviews, Vol. 8, Issue. 3, p. 123.


    Owen, Catherine Rees, Anne-Marie and Parker, Gordon 2008. The role of fatty acids in the development and treatment of mood disorders. Current Opinion in Psychiatry, Vol. 21, Issue. 1, p. 19.


    Rees, Anne-Marie Austin, Marie-Paule and Parker, Gordon B. 2008. Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Australian and New Zealand Journal of Psychiatry, Vol. 42, Issue. 3, p. 199.


    ×

To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects

  • MARIE-PAULE AUSTIN (a1)
  • DOI: http://dx.doi.org/10.1017/S003329170600835X
  • Published online: 01 July 2006
Abstract

Recent pharmaceutical company and regulatory body circulars warning against the use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy have left clinicians in somewhat of a quandary as to how to manage their more severely depressed patients in pregnancy. Conversely, up to 75% of depressed women ceasing their antidepressants periconceptually will relapse. Studies reporting on adverse neonatal outcomes following exposure to SSRIs in the latter half of pregnancy suggest that the fetus is exposed to significant concentrations of these medications during this time. Adverse neonatal effects affecting the respiratory, gastrointestinal and neurological systems are, however, predominantly mild and self-limiting. One small retrospective case study suggests that SSRI exposure in the latter half of pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the neonate (PPHN), however, the absolute risk of developing PPHN remains very small and these findings will require replication with a prospective study. While the studies to date suggest the need to closely monitor SSRI-exposed neonates in the immediate postnatal period, preferably with a neonatal withdrawal scale and access to neonatology services, there is currently no clear argument for women to be weaned off their SSRI in late pregnancy. The decision to use SSRIs at this time will have to be made on a case-by-case basis in close consultation with the mother and her partner.

Copyright
Corresponding author
Department Liaison Psychiatry, Prince of Wales Hospital, High Street, Randwick, NSW, Australia, 2031. (Email: m.austin@unsw.edu.au)
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×